Rivervest |

14 Dec Archmont Biopharma, Inc.

Posted at 15:35h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOArchmont, a company co-founded by RiverVest, is developing bone-targeted gene therapy for patients with a rare lysosomal storage disorder known as Morquio A syndrome, leveraging lysosome expertise at Saint Louis University and...

14 Dec Amplyx Pharmaceuticals, Inc.

Posted at 15:32h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAmplyx is focused on developing innovative therapies for debilitating and life-threatening systemic fungal and viral infections in patients with compromised immune systems. Amplyx is advancing programs with the potential to protect these...

14 Dec Curzion Pharmaceuticals, Inc.

Posted at 15:21h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CACurzion Pharmaceuticals is developing a late-stage small molecule to treat fibrotic conditions, where significant unmet needs exist. The safety and efficacy of its in-licensed lead development candidate have been demonstrated in prior...

14 Dec Good Therapeutics, Inc.

Posted at 15:19h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAGood Therapeutics is an early-stage biotechnology company developing context-dependent protein drugs that sense biomarkers which trigger therapeutic activity. Good Therapeutics’ goal is to make safer, more effective drugs that act only when and...

14 Dec Neuros Medical, Inc.

Posted at 15:09h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Cleveland, OHNeuros Medical is focused on the development of proprietary electrical stimulation therapies for the treatment of chronic pain. The Company’s patented platform technology, Electrical Nerve Block, aims to treat a variety of indications,...

14 Dec Standard Bariatrics, Inc.

Posted at 14:48h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Cincinnatio, OHStandard Bariatrics is committed to creating superior surgical products for sleeve gastrectomy bariatric surgery. The company is commercializing its FDA-cleared STANDARD CLAMP™ and is developing a full-length stapler that would enable surgeons to...

14 Dec Cabrellis Pharmaceuticals Corporation

Posted at 14:04h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CACabrellis developed Calsed™, a third-generation synthetic anthracycline drug for small-cell and non-small-cell lung cancers.Acquired by Pharmion (now part of Celgene) in November 2011.CELGENE.COM © Copyright RiverVest® All Rights Reserved....

14 Dec Cameron Health, Inc.

Posted at 14:01h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Clemente, CACameron Health developed the world’s first commercially-available subcutaneous implantable cardioverter defibrillator, called the S-ICD System. No leads are placed in or on the heart, leaving the heart and blood vessels untouched and...

14 Dec Centerre Healthcare Corporation

Posted at 13:59h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Nashville, TN Healthcare ServicesFounded in St. Louis, Centerre Healthcare developed and operated inpatient rehabilitation hospitals, providing inpatient services in partnership with general acute-care hospitals. Through a focused approach, Centerre achieved better outcomes on a...

14 Dec CGI Pharmaceuticals Inc.

Posted at 13:57h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Branford, CTCGI Pharmaceuticals discovered and generated a library of small molecules with a focus on kinase biology. The lead preclinical compound targeted spleen tyrosine kinase (SyK) with potential applications in the treatment of serious...

14 Dec Conforma Therapeutics Corporation

Posted at 13:52h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAConforma Therapeutics discovered and developed drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in protecting and supporting the growth of cancer cells across a range of tumor types,...

14 Dec CyDex Pharmaceuticals, Inc.

Posted at 13:51h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Lenexa, KSCyDex Pharmaceuticals, Inc. developed Captisol®, a drug delivery technology that can significantly improve the solubility, stability and bioavailability of active pharmaceutical ingredients. Captisol is a doughnut-shaped cyclodextrin molecule that holds a drug in...

14 Dec Excaliard Pharmaceuticals, Inc.

Posted at 13:48h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAExcaliard Pharmaceuticals focused on the development of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. Its lead compound, EXC 001, was an antisense oligonucleotide drug targeting...

14 Dec IDEV Technologies, Inc.

Posted at 13:37h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Houston, TXIDEV Technologies, Inc. developed the Supera™ stent for the treatment of peripheral artery disease. The use of interwoven, individual, flexible nitinol wires enables a unique combination of high compression resistance, low chronic outward...

13 Dec Lumena Pharmaceuticals, Inc.

Posted at 21:23h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CALumena developed a drug for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. If left untreated, these conditions can lead to liver failure...

13 Dec MacroGenics, Inc.

Posted at 21:17h in by Rivervest 0 Comments

/ PORTFOLIO /*! elementor - v3.11.1 - 15-02-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Rockville, MDIPO October 2013 (NASDAQ: MGNX)MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of...